better tolerated migraine preventive treatments are anxiously expected. Until then, exciting results on combining available drugs may fulfill the upcoming horizon for relieving the burden of migraine.
-Migraine is a genetically inherited disease, which involves a brain hiper excitable state
-Neurotransmitter dysfunction, probably related to a calcium channelopathy, is also involved in migraine
-The neurotransmitter dysfunction probably results in a state of central dysnociception and/or dysmodulation
-Neuromodulators are effective migraine preventive pharmacological agents through the decreasing of neuronal excitability
-Some neuromodulators are proven effective. Others may be used, but further evidence of their efficacy is still lacking
-The combination of two neuromodulators may useful for some patients who don't tolerate full doses of individual drugs or need better efficacy outcomes
-The future of migraine preventive treatment may involve two or more drugs aiming at different mechanisms of action and/or brain circuits
1.Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology. 1994;44(suppl 14):S24-S39.
2.Rasmussen BK. Epidemiology of headache. Cephalagia. 1995;15:45-68)
3.Goadsby PJ. Pathophysiology of migraine. In: Silberstein SD, Lipton RB, Dalessaio DJ (eds.) Wolff's Headache and Other Head Pain. 7thedition. Oxford University Press, Oxford. 2001:57-72.
4.May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiology implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19(2):115-27.
5.Welch KM, Barkley GL, Tepley N, Ramadan NM. Central neurogenic mechanisms of migraine. Neurology. 1993;43(6 Suppl 3):S21-5.
6.Goadsby PJ, Lipton RB, Ferrari MD. Migraine current understanding and treatment. N Engl J Med. 2002;346(4):257-
70.Comment in: N Engl J Med. 2002;347(10):764-6; author reply 764-6.
7.Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM,, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543-52.
8.De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante
Headache Medicine, v.2, n.4, p.173-81, Oct/Nov/Dec. 2011
L, et al. Haploinsufficiency of ATP1A2 encoding Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type
2. Nat Genetics. 2003; 33(2):192-6.
9.Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990;8(4):817-28.
10.Welch KM. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache. 2005;45[Suppl 1]:S25S32.
11.Mathew NT. Antiepileptic drugs in migraine prevention. Headache. 2001;41[Suppl 1]:S18-S24.
12.Cutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001;41[Suppl 1]:S3-S10.
13.Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281-6.
14.Tringali G, Aubry JM, Moscianese K, Zamori C, Vairano M, Preziosi P, et al. Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J Psychiatry Neurosci. 2004; 29(6):459-66.
15.Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000;40(9):720-3.
16.Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep. 2004;8(2):91-5.
17.Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 1996;36(9):547-55.
18.White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999; 40(suppl 5):S2-S10)
19.Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004 Apr;61(4):490-5.
20.Potter DL, Hart DE, Calder CS, et al. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. (Abstract) Neurology 2000;54(suppl 3):A15. *of interest. First study to demonstrate efficacy of TPM in migraine
21.Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU A multi-center double-blind pilot comparison of onabotulinumtoxin A and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21-32.
22.Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci. 2010;31 (Suppl 1):S175-7.
23.Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep. 2011;15(1):64-9.
24.Sigel E. Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorylation. J Recept Signal Transduct Res. 1995;15(1-4):325-3.
25.Adelman J, Freitag FG, Lainez M, Shi Y, Ascher S, Mao L, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9(2):175-85.